PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival-Reference-Cited by-同舟云学术

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival

Published:2021-03-11 Issue:6 Volume:13 Page:8975-8988
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Shao Fengping¹,Duan Yaoyun²,Zhao Yunhe¹,Li Yinguang¹,Liu Jun¹,Zhang Cai¹,He Shanyang³

Affiliation:

1. Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong, China

2. Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China

3. Department of Gynecology and Obstetrics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance;Frontiers in Oncology;2024-06-27

2. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer—Genetic Instability and Clinical Implications;Cells;2024-02-15

3. Targeting the DNA repair pathway for breast cancer therapy: Beyond the molecular subtypes;Biomedicine & Pharmacotherapy;2023-12

4. A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer;Current Oncology;2023-10-19

5. BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis;BMC Cancer;2023-08-29